arrow_back Trending Legislation
Share share

Greater Drug Discount Transparency: Lower Costs for Patients

This act aims to increase transparency regarding drug discounts and rebates negotiated by pharmacy benefit managers (PBMs). Citizens will gain access to information on how these discounts affect drug prices, potentially leading to lower healthcare costs. The information will be publicly available while protecting sensitive data.
Key points
Public disclosure of drug discount and rebate information starting January 1, 2022.
Data will be available on the Department of Health and Human Services website, grouped by drug class.
The goal is to allow comparison of how pharmacy benefit managers pass on negotiated discounts to patients and insurance plans.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Improving Transparency to Lower Drug Costs Act of 2021
Print number: HR 3682
Sponsor: Rep. Spanberger, Abigail Davis [D-VA-7]
Process start date: 2021-06-01
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Greater Drug Discount Transparency: Lower Costs for Patients

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 3682.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-06-01.

What are the main provisions?

Key points include:

  • Public disclosure of drug discount and rebate information starting January 1, 2022.
  • Data will be available on the Department of Health and Human Services website, grouped by drug class.
  • The goal is to allow comparison of how pharmacy benefit managers pass on negotiated discounts to patients and insurance plans.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Spanberger, Abigail Davis [D-VA-7].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

Analysis and Potential Impact of HR 3682

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health